Benchmarking the performance of complex analytical pipelines is an essential part of 3 developing Laboratory Developed Assays (LDT). Reference samples and benchmark calls 4 published by Genome in a Bottle (GIAB) Consortium have enabled the evaluation of 5 analytical methods. However, the performance of such methods is not uniform across the 6 different regions of the genome/exome and different variant types and lengths. Here we 7 present a scalable and reproducible, cloud-based benchmarking workflow that can be used by 8 clinical laboratories to rapidly access and validate the performance of LDT assays, across 9 their regions of interest and reportable range, using a broad set of benchmarking samples. 10 11
Background

16
Next Generation Sequencing (NGS) and analytical methods developed to detect various 17 forms disease-causing polymorphisms are now routinely being used by clinical laboratories 18 to determine the molecular etiology of complex diseases/disorders and in many cases to make 19 critical treatment course decisions. In the past two decades, many polymorphisms in the 20 human genome have been identified and validated that serve as predictive, diagnostic, and 21 prognostic markers for complex inherited diseases. These genomic disease markers can be of 22 different forms such as Single Nucleotide Variants (SNVs), small INsertions and DELetions 23 (INDELs), large deletions and duplications (del/dups), and Copy Number Variations (CNVs) 24 and can vary in size from a single base change to several Mega Bases (MB) in length and 25 even whole chromosomal polysomy. Clinically relevant polymorphisms occur in different 26 regions of the genome, including exonic, splice-sites, and deep-intronic regions. These 27 polymorphisms also happen in various forms, including single base changes within high 28 entropic regions, copy number changes to homopolymer repeats and copy number changes to 29 Short Tandem Repeat (STR) regions. NGS platforms used to detect these polymorphisms; 30 owing to their different sequencing chemistry and signal processing methods; have very 31 different error modes and hence very different analytical performance across the different 32 regions of the genome. Consequently, analytical methods specific to various NGS platforms 33 such as Illumina, Ion Torrent, Pacific Biosciences, and Oxford Nanopore have been 34 developed to both account for and correct the errors particular to these sequencing platforms. 35 This has resulted in a dizzying array of combinations of sequencing platforms and analytical 36 methods available to a clinical diagnostic laboratory to develop their LDT assay. 37 38
Benchmarking methods and pipelines are essential to accurately assess the performance of 39 sequencing platforms and analytical methods before they are incorporated into clinical 40 diagnostic assays. Genome In A Bottle (GIAB) consortium hosted by NIST has characterized 41 the pilot genome (NA12878/HG001) (1) and six samples from the Personal Genome Project 42 (PGP) (2). These benchmark calls for SNVs and small INDELs (1-20bp) from reference 43 samples can be used for optimization, performance estimation, and analytical validation of 44 LDT assays using complex analytical pipelines with multiple methods to detect 45 polymorphisms in the genome. samples. This is attributable to the fact that many genes have isoforms, resulting in higher 110 alignment errors, and some genes have either very high or very low GC content, resulting in 111 higher than average sequencing errors within these regions of the genome. The finding is of 112 great clinical significance, since the reportable region of most inherited disease/disorder, 113
LDT assay is limited to the clinically relevant genes and thereby the overall performance 114 characteristics of the assay is better than that estimated over either the whole genome or 115 whole exome regions. 116 117 The benchmarking results of the other GIAB reference samples in the clinically relevant and 136 whole exome regions can be obtained in the Supplementary Materials Table S1-S4 and Table  137 S5-S8, respectively. The histogram for the indel size distribution in the NA24385 reference 138 sample for the whole exome region is in Supplementary Material as Fig S1 . The histograms 139 of indel size distributions for GIAB samples in both the whole exome and clinically relevant 140 regions are available in our github repository -vandhana/stanford-benchmarking-workflows. 141 142 
Scalability and Reproducibility of Benchmarking workflow
The benchmarking workflow is designed to be repeatable and reproducible by using Docker 269 containers for all software and bioinformatics components used within the workflow (see 270 In addition to the GIAB reference samples, samples with known pathogenic germline variants 295 (see Table 2 .) for various inherited diseases/disorders were chosen from Genetic Testing 296
Reference Materials Coordination Program (GeT-RM) (26-30) 297 298 Table 7 . GeT-RM sample ids and location of ground-truth variants in GRCh37 coordinates. 299 300 Consent for publication 379 The authors declare that they have no competing interests. 380 381
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